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Available online 10 April 2008The CD8+ T cell responses directed toward the VP1 antigens of human polyomaviruses JC and BK recently were
shown to be cross-reactive. Two HLA-A⁎0201-restricted determinants from each virus have been deﬁned and
include JCp100–108 (ILMWEAVTL) and BKp108–116 (LLMWEAVTV) aswell as JCp36–44 (SITEVECFL) and BKp44–
52 (AITEVECFL). We asked whether VP1 from the related SV40 contains similar HLA-A⁎0201-restricted
determinants. In this study, we demonstrate that CD8+ Tcells speciﬁc for SV40 VP1 p110–118 (ILMWEAVTV), but
not p46–54 (SFTEVECFL), can be induced in HLA-A⁎0201-transgenic mice and that these CD8+ T cells cross-react
with the corresponding determinants from JC and BK virus. The SV40 p110 determinant was found to be
processed and presented in SV40-infected cells. These results indicate that the JCp36/BKp44 determinants are
distinctive for the humanpolyomaviruseswhile the JCp100/BKp108/SVp110 determinants are shared by all three
viruses, providing a target for CD8+ T cell cross-reactivity.
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The polyomaviruses JC and BK infect a high proportion of the human
population, with prevalence reported up to 60% seropositivity for JC
virus and up to 90% seropositivity for BK virus by adulthood (Dorries
et al.,1994; Padgett andWalker,1973; Taguchi et al.,1982). These viruses,
acquired during childhood and adolescence, persist for the lifetime of
the host but are only associatedwith human disease following the onset
of immune suppression, implicating the immune response in lifelong
control of these viruses. JC virus is the causative agent of progressive
multifocal leukoencephalopathy (PML) (Padgett et al., 1971), a neuro-
logical disorder resulting fromdemyelination followingdestruction of JC
virus-infected oligodendrocytes within the brains of AIDS patients
(Antinori et al., 2001). Increased levels of BK virus in the kidneys are
associated with nephropathy in renal transplant patients undergoing
immunosuppressive therapy, often resulting in kidney failure (Rand-
hawa and Brennan, 2006). In addition, high level BK viremia has been
observed in associationwith late-onset hemorrhagic cystis in immuno-
suppressed bone marrow transplant patients (Arthur et al., 1986; Bedi
et al., 1995; Childs et al., 1998).artment of Microbiology and
531 0477.
l rights reserved.The cellular immune response directed against the human polyoma-
viruses has recently been characterized. Koralnik and colleagues ﬁrst
deﬁned the HLA-A⁎0201-restricted CD8+ Tcell response toward determi-
nants in the VP1 antigen of JC virus in PML patients, ﬁnding a positive
correlation between the presence of VP1-reactive CD8+ T cells and
prolonged survival (Du Pasquier et al., 2001; Koralnik et al., 2001). HLA-
A⁎0201-restricted determinants corresponding to JC VP1 residues 100–
108 (p100) (Koralnik et al., 2002) and 36–44 (p36) (Du Pasquier et al.,
2003) were deﬁned using CD8+ Tcells isolated from PML patients as well
as healthy controls (Du Pasquier et al., 2004). Subsequent studies
demonstrated the presence of HLA-A⁎0201-restricted determinants in
theVP1antigenofBKvirus, corresponding toVP1 residues108–116 (p108)
and 44–52 (p44), using both healthy subjects and kidney transplant
recipients undergoing immunosuppressive therapy (Krymskaya et al.,
2005). However, CD8+ T cells recognizing the BK VP1 determinants p108
and p44 were found to cross-react with the corresponding determinants
from JC VP1 (Koralnik et al., 2002; Krymskaya et al., 2005). Thus, cross-
reactive CD8+ T cells initiated by one polyomavirus may provide some
level of existing immunity toward related polyomaviruses.
The closely related Simian virus 40 (SV40) has recently come under
scrutiny regarding its possible link with several human cancers. SV40
was discovered in the early 1960's as an accidental contaminant of
formalin-inactivated (Salk) polio vaccines grown in rhesus monkey
kidney cells (Sweet and Hilleman, 1960). The virus was originally
Fig. 1. Sequence and peptide/MHC stability of HLA-A⁎0201-restricted polyomavirus VP1
determinants. A: Comparison of human polyomavirus VP1 determinants and the
corresponding sequences from SV40 VP1. Residues with underlines vary from the JC
virus sequence. B: VP1 peptide-induced stabilization of HLA-A⁎0201 surface expression.
Peptides were incubatedwith T2 cells at the indicated concentrations overnight at 37 °C
and then stained for expression of HLA-A⁎0201. The control H-2Kb-binding peptide
gB498–505 from Herpes simplex virus was used as a negative control.
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1962; Girardi et al., 1962) and to transform multiple cell types in vitro
due to expression of the viral early region gene products, including the
oncoprotein large Tantigen (Butel et al.,1972).DNA sequences speciﬁc to
SV40 have been reported to be present in a proportion of several human
cancers including mesothelioma, non-Hodgkins lymphoma, pediatric
brain tumors and osteosarcomas [reviewed in (Engels, 2005; Vilchez
and Butel, 2004)]. Multiple laboratories have detected SV40 sequences
in such human tumors using PCR-based approaches, in some cases
conﬁrming their authenticity by DNA sequence analysis. This issue
remains controversial, however, due to publication of some results
which failed todetect SV40sequences in these same types of tumors and
due to the absence of high level SV40-speciﬁc serological responses inFig. 2. The SVp110 determinant is immunogenic in HHDII mice. Groups of 3 HHDII mice were
Mice received a booster immunization after twoweeks and spleens were harvested after a fu
immunizing peptide and cultured for 6 days. Responder cells were tested for their ability to p
percentage of CD8+ T cells that produced IFN-γ is indicated in each dot plot. This experimetumor patients [reviewed in (Shah, 2007)]. The prevalence of the closely
related human polyomaviruses, JC and BK, in the human population has
caused concern that both PCR and serological results could be tainted by
contamination or cross-reactivity, respectively. In particular, the low
level serological response to SV40 detected in humans has been
attributed to cross-reactivity of BK and JC virus-induced antibodies
toward SV40 (Viscidi et al., 2003). This is not surprising given the high
degree of homologyamong these polyomaviruses at both thenucleotide
(Frisque, 1983) and amino acid level (Mann and Carroll, 1984).
Previous investigations in mice revealed cross-reactivity of SV40 T
antigen-induced CD8+ T cells toward the T antigens of BK and JC virus
(Tevethia et al., 1998). In the current report, we investigated whether
SV40 VP1 contains determinants similar to the known HLA-A⁎0201-
restricted JC and BK determinants in VP1 and whether CD8+ T cells
responsive toward SV40 VP1 are cross-reactive with the corresponding
human polyomavirus determinants. Using line HHDII mice, which
express the human HLA-A⁎0201 molecule, we assessed a) the immu-
nogenicity of the heterologous VP1 peptide determinants from SV40, b)
the cross-reactivity of SV40-responsive CD8+ T cells toward JC and BK
VP1 determinants and vice versa and c) whether the SV40 VP1 deter-
minants are naturally processed and presented from SV40-infected cells.
Results
SV40 peptide p110, but not peptide p46, binds to HLA-A⁎0201
SV40VP1peptides that correspond to the known epitopes from JC and
BK virus VP1 include peptide 110–118 (SVp110) and peptide 46–54
(SVp46). The sequences are shown in Fig. 1A for comparison with those
from the human polyomaviruses. SVp110 differs from the corresponding
JC and BK peptides by only a single amino acid with conservative changes
of leu⇒val at position 9 compared to JCp100 and leu⇒ile at position 1
compared to BKp108. However, SVp46 varies from the corresponding JC
and BK peptides at both positions 1 and 2, with the critical anchor residue
at position 2 changed from Ile to a bulky phe residue,which is not favored
for peptides that bind to HLA-A⁎0201 (Rammensee et al., 1995).
Using the TAP-deﬁcient T2 cell line, we determined the ability of
titrated amounts of each VP1 peptide to stabilize HLA-A⁎0201
molecules on the cell surface following overnight incubation. The
results demonstrate that the efﬁciency of SVp110 peptide to stabilize
HLA-A⁎0201 was similar to that achieved with JCp100 and BKp108
peptides (Fig.1B). In contrast, no HLA-A⁎0201 expressionwas detected
following incubation of T2 cells with SVp46 while JCp36 and BKp44immunized subcutaneously with 100 μg of peptides SVp110 or SVp46 emulsiﬁed in IFA.
rther 7 days. Spleen cells were restimulated in vitro with syngeneic DCs pulsed with the
roduce IFN-γ following stimulation with the indicated peptides and stained by ICS. The
nt was performed three times using three mice per group and achieved similar results.
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concentrations of 10 μM and above. These results indicate that the
SVp110 peptide, but not the SVp46 peptide, binds efﬁciently to HLA-
A⁎0201. Lack of efﬁcient binding to HLA-A⁎0201 by SVp46 is likely due
to the absence of the isoleucine residue at position 2, predicted to be
critical for binding to HLA-A⁎0201.Fig. 3. CD8+ Tcells responsive to SVp110 are detected directly ex vivo and are highly cross-rea
were immunized with the indicated VP1 peptides as described in Fig. 2 and received a boost
subjected to ICS for IFN-γ following a 6 h stimulation with the same peptide used for immu
produced IFN-γ is indicated in each dot plot. B. Splenocytes from Awere restimulated in vitro
ICS for IFN-γ production following stimulation for 6 hwith titrated amounts of each of the ind
a given peptide concentration. This experiment was performed twice using three mice perThe SVp110 peptide is immunogenic in HHDII mice
To determine whether the SV40 VP1 peptides were immunogenic,
line HHDII micewere immunized with either SVp110 or SVp46. After a
booster immunization, splenocytes were restimulated in vitro with
peptide pulsed irradiated syngeneic DCs and then analyzed after sixctivewith determinants from the human polyomaviruses. A: Groups of three HHDII mice
er immunization after one week. After a further 7 days, spleen cells were harvested and
nization or the Gag p17 peptide derived from HIV. The percentage of CD8+ T cells that
for 6 days with syngeneic DCs pulsed with the immunizing peptide and then tested by
icated peptides. Data are plotted as the percentage of CD8+ Tcells that produced IFN-γ at
group and gave similar results to those shown.
186 H.R.S. Tagaram et al. / Virology 376 (2008) 183–190days by intracellular cytokine staining (ICS) for the presence of CD8+ T
cells responsive toward either the immunizing peptide or the
corresponding peptides from BK and JC VP1. The results demonstrate
that immunization with SVp110, but not SVp46, yielded CD8+ T cells
capable of producing IFN-γ in response to the immunizing peptide
(Fig. 2). The ﬁnding that SVp46 failed to induce a detectable CD8+ T
cell response is not surprising given the poor binding of this peptide to
HLA-A⁎0201. CD8+ T cells induced by immunization with SVp110 also
responded to JCp100 (49.3%) and BKp108 (49.8%) at nearly identical
frequencies as achieved with SVp110 (49.6%), suggesting that these T
cells are cross-reactive, at least at the high concentration of peptide
tested in this assay (Fig. 2).
Cross-reactivity among VP1-responsive CD8+ T cells
Since such a large proportion of the CD8+ T cells responded to
SVp110 following one week of culture, we asked whether these cells
could be detected directly ex vivo following immunization of HHDII
mice with this peptide. In addition, groups of HHDII mice were
immunized with the JCp100 and BKp108 peptides for comparison. As
shown in Fig. 3A, CD8+ T cells responsive to each of the three peptides
were detected in 3 of 3 mice with an average frequency of 5.6% for
SVp110, 2.45% for JCp100 and 3.64% for BKp108. Thus, HHDII mice
develop a robust response to SVp110 as well as to the corresponding
peptides from JC and BK VP1 following a prime/boost immunization.Fig. 4. Endogenously expressed VP1 determinants induce cross-reactive CD8+ T cell popul
SVp110 or ES-SVT281. Ten days following immunization, spleens were harvested and evalua
percentage of CD8+ T cells responsive to each peptide is indicated in the dot plots. Data areTo determine the efﬁciency of cross-recognition among the VP1-
responsive CD8+ T cells, splenocytes were expanded in vitro for six
days with the immunizing peptide and the responder cells tested for
their ability to produce IFN-γ following stimulation with titrated
amounts (100 to 0.1 nM) of each of the heterologous peptides by ICS.
CD8+ T cells induced by immunization with SVp110, recognized all
three peptides with similar efﬁciencies, although there was a slight
decrease (5 to 10-fold) in the efﬁciency of cross-recognition of JCp100
by these T cells (Fig. 3B). For 2 of 3 cultures derived from JCp100
immunized mice, the response to all three peptides was similar, with
T cells from the remaining culture having an increased sensitivity to
JCp100 relative to the other two peptides. For T cells induced by
immunization with BKp108, the response to the immunizing peptide
was consistently most efﬁcient, with the response toward SVp110
reduced about 5-fold and that to JCp100 about 10-fold. Thus, CD8+
T cells induced by immunization with SVp100 are cross-reactive with
the JC and BK corresponding determinants and vice versa, although
the efﬁciency is reduced in some cases toward the corresponding
peptides from the related viruses.
Vaccinia virus encoded SVp110 also induces cross-reactive CD8+ T cells
Our results demonstrate that peptide-induced CD8+ Tcells are cross-
reactive toward the heterologous VP1 determinants. To rule out the
possibility that the observed CD8+ T cell cross-reactivity is aations. HHDII mice were immunized with rVVs expressing ES-JCp100, ES-BKp108, ES-
ted by ICS for IFN-γ production following stimulation with the indicated peptides. The
representative of two independent experiments with three mice per group.
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recombinant vaccinia viruses (rVV) that express the VP1 determinants
asminigenes preceded by an endoplasmic reticulum targeting sequence
(ES). This method induces potent CD8+ T cell responses which can be
detected directly ex vivo (Fu et al., 1998). Groups of HDDII mice were
immunized with 107 PFU of rVV-ES-JCp100, rVV-ES-BKp108, rVV-ES-
SVp110or the control rVV-ES-SVT281encoding the knownHLA-A⁎0201-
restricted epitope from SV40 T antigen (Schell et al., 2001). Splenocytes
were analyzed by ICS after 10 days (Fig. 4). All mice demonstrated a
detectable ex vivo response toward the determinant used for immuniza-
tion and, as demonstrated with peptide immunized mice, a similar
proportion of cells responded to the heterologous peptides. We
consistently observed that mice immunized with rVV-ES-JCp100 had
similar responses toward all three corresponding VP1 epitopes while
mice immunized with rVV-ES-BKp108 and rVV-ES-SVp110 responded
more efﬁciently toward both BKp108 and SVp110 peptides than toward
JCp100 — a trend also observed following peptide immunization (see
Fig. 3B). Splenocytes from rVV-ES-SVT281 immunized mice responded
only to peptide SVT281, indicating that the vaccinia virus immunizations
were speciﬁc for the indicated minigenes. These data demonstrate that
de novo production of JC, BK, and SV40 VP1 epitopes in HHDII mice also
recruits CD8+ T cells that are generally cross-reactive toward the poly-
omavirus determinants.
The SV40 VP1 p110 determinant is naturally processed and presented in
SV40 infected cells
To determine whether the SVp110 determinant is naturally
processed and presented from VP1 following SV40 infection, the
ability of CD8+ T cells derived from SVp110 immunized mice to lyse
SV40 infected TC7 monkey cells was determined. Since TC7 cells do
not express the proper MHC molecule, SV40 infected TC7 cells were
co-infected with rVV-A2.1, expressing HLA-A⁎0201, or rVV-Kd,
expressing the mouse H-2Kd molecule. As shown in Fig. 5, SVp110-
induced T cells efﬁciently lysed SV40-infected target cells co-expres-
sing HLA-A⁎0201 in a dose-dependent manner above the backgroundFig. 5. The SV40 epitope recognized by SVp110-induced CD8+ T cells is naturally
processed and presented from SV40 infected cells. HHDII CD8+ T cell lines induced by
peptide immunization with SVp110 (A) or SVT281 (B) and maintained by in vitro
restimulationwere tested for their ability to lyse SV40-infected (48 h) TC7 monkey cells
co-infected with either rVV-A2.1 or rVV-Kd in a 4-hour 51Cr-release assay. The effector:
target ratio (E:T) is indicated.level of lysis obtained on the same cells co-expressing H-2Kd (Fig. 5). As a
positive control, CD8+ T cells speciﬁc for the known HLA-A⁎0201-
restricted epitope T281 from SV40 T antigen efﬁciently lysed SV40 in-
fected target cells co-expressing HLA-A⁎0201, but not cells co-expressing
H-2Kd. These results indicate that the SVp110 determinant is naturally
processed and presented from VP1 protein in the context of HLA-A⁎0201
and, therefore, represents a target epitope on SV40-infected cells.
Discussion
Wehave identiﬁed anaturally processed andpresented epitope from
the SV40major capsidproteinVP1,which is recognized byHLA-A⁎0201-
restricted CD8+ T cells in line HHDII transgenic mice. This determinant,
SVp110, shares extensive sequence homology with the previously
identiﬁed determinants from BK and JC virus VP1, such that CD8+
T cells induced by one determinant are cross-reactive with the corres-
ponding determinants from the other two viruses. In contrast, SVp46
failed to induce a detectable CD8+ T cell response in HHDII mice, most
likely due to the presence of a phenylalanine residue at the position
2 anchor position which likely disrupts binding to HLA-A⁎0201. Thus,
only oneof two knownVP1determinants is commonbetweenSV40 and
the human polyomaviruses.
In humans, cross-reactivity of CD8+ T cells toward VP1-derived BK
and JC determinants was ﬁrst demonstrated by Krymskaya et al.
(Krymskaya et al., 2005) in both healthy individuals and kidney
transplant recipients with active BK virus infections and later by Chen
et al. (Chen et al., 2006) in kidney transplant recipients with poly-
omavirus nephropathy. Using co-stainingwithMHC tetramers speciﬁc
for JCp100 and BKp108, both studies revealed extensive cross-
reactivity of in vitro stimulated human CD8+ T cells toward the
corresponding determinants. Chen et al. (Chen et al., 2006) addition-
ally demonstrated cross-reactivity of in vitro cultured CD8+ T cells
toward the JCp36 and BKp44 determinants using the same approach.
Of note in both studies, a minor population of CD8+ T cells with single
speciﬁcity was apparent from the MHC tetramer staining, suggesting
that some CD8+ T cell clones may be able to distinguish between the
epitopes from different polyomaviruses. In our study, peptide titration
assays revealed some differences in the avidity of CD8+ T cells toward
heterologous determinants by bulk CD8+ T cell populations, with the
most efﬁcient response targeted against the immunizing peptide.
Favored recognition of the immunizing peptide might indicate either
the presence of some CD8+ T cells with speciﬁcity only for the
immunizing peptide or the recruitment of CD8+ T cell clones with
increased avidity for the immunizing peptide. We favor the second
possibility since differences in the frequencyof CD8+ Tcells responding
toward heterologous peptides was most noticeable at limiting
peptide concentrations.
Krymskaya et al. (Krymskaya et al., 2005) immunized HHDII mice
with a recombinant vaccinia virus expressing the BK virus full length
VP1 protein. Subsequent analysis revealed that the responding CD8+
T cells in HHDII mice were cross-reactive with JCp100, although fewer
cells responded to the JCp100 peptide compared to the BKp108
peptide. We additionally show here that CD8+ T cells derived from
HHDII mice immunized with either BKp108 or JCp100 peptide or
vaccinia virus encoded minigenes are largely cross-reactive toward
the SVp110 peptide and that mice immunized against JCp100 cross-
react with both BKp108 and SVp110. Thus, the HHDII T cell repertoire
mimics the cross-reactive nature of the human T cell repertoire in
response to the polyomavirus VP1 determinants.
Although we found that the SVp46 peptide was not immunogenic
in HHDII mice, a recent study by Li et al. (Li et al., 2006) showed that
human CD8+ Tcells expanded from PBMCs of healthy individuals by in
vitro stimulation with BKp44 peptide cross-react on both JCp36 and
SVp46 in an intracellular cytokine staining assay. This apparent
discrepancy might be explained by the use of high concentrations of
peptides during the in vitro assay. Indeed, we found in a preliminary
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peptide immunization and that the responding Tcells produce IFN-γ in
response to 1 μMSV40 p46 (data not shown).Whether the responding
JCp36- and BKp44-induced CD8+ T cells can recognize reduced
concentrations of the SVp46 peptide remains to be determined.
Overall, our data demonstrating that the SVp46 peptide fails to induce
stabilization of HLA-A⁎0201 or induce a detectable T cell response in
HHDII mice suggests that inefﬁcient binding of this peptide to MHC
class Imoleculesmay limit its immunogenicity and antigenicity in vivo.
The signiﬁcance of CD8+ T cell cross-reactivity toward VP1 determi-
nants in humans has not been elucidated, but studies of heterologous
virus immunity in experimental models indicate that preferential
expansion of cross-reactive T cells by heterologous viruses can skew
immunodominance patterns toward cross-reactive epitopes and away
from virus-speciﬁc responses (Brehm et al., 2002). In fact, attrition of
memory T cells targeting virus-speciﬁc responses was observed in some
cases (Selin et al., 1999, 1996). In the case of persistent polyomavirus
infections, cross-reactive immunity may preferentially enhance immu-
nity against multiple polyomaviruses but may limit the development of
speciﬁc virus immunity that would serve as a signature for active virus
infection, an issue raised during previous studies of CD8+Tcell responses
to BK and JC viruses (Chen et al., 2006; Krymskaya et al., 2005).
Our results raise the possibility that existing human polyomavirus-
induced VP1-responsive memory CD8+ T cells could cross-react with
SVp110 in potentially SV40 exposed humans. Because SV40 is thought
to replicate poorly in most human cells compared to the human
polyomaviruses (O'Neill et al., 1990), lack of robust virus replication
coupled with the presence of both polyomavirus-induced cross-
reactive antibodies and memory T cells targeting VP1 could mask an
SV40-speciﬁc immune signature. In addition, our study suggests that
T cells targeting the SVp110 determinant, but not SVp46 could expand
by exposure to SV40. Interestingly, Chen et al. (Chen et al., 2006) found
that CD8+ T cells speciﬁc for BKp108 were favored over CD8+ T cells
speciﬁc for BKp44 in kidney transplant recipients with active BK virus
infections, while healthy individuals had the reverse proﬁle. Thus, one
consequence of cross-reactive immunity toward the polyomaviruses
could be that little to no SV40-speciﬁc responses would be detected in
humans with pre-existing polyomavirus immunity, providing an
alternate explanation for the absence of evidence for a strong virus-
speciﬁc immune response to SV40 infection in humans.
While VP1-directed CD8+ T cells and antibodies could provide
protection against SV40 infection, immunity directed against this late
gene product would have little effect on tumors expressing SV40
T antigen. In fact, the VP1-targeted cross-reactive immune response
might initially serve to limit responses toward any virus-speciﬁc
determinants in T antigen. A few studies have demonstrated the exis-
tence of HLA-restricted determinants in T antigen recognized by CD8+
T cells. Three HLA-A⁎0201-restricted determinants have been deﬁned
for SV40 T antigen encompassing residues 281–289 (Schell et al., 2001),
285–293 (Bright et al., 2002) and 577–585 (Velders et al., 2001) with
CD8+ T cells speciﬁc for peptide 285–293 shown to be present in a
mesothelioma patient (Bright et al., 2002). However, more studies are
required to determine any association of T antigen-speciﬁc CD8+ T cell
responses with individuals potentially exposed to SV40.
In summary, our results demonstrate that the SV40 VP1 determi-
nant p110–118 is immunogenic in HHDII mice, is naturally processed
and presented by HLA-A⁎0201 in virus-infected cells and the res-
ponding CD8+ T cells are highly cross-reactive with the corresponding
determinants from the human polyomaviruses.
Materials and methods
Mice
HHDII mice express a chimeric MHC class I molecule composed of
the cytosolic, transmembrane and α3 domains of H-2Db and the α1and α2 domains of HLA-A⁎0201 covalently linked to the human β2 m
light chain (Pascolo et al., 1997). In addition, these mice are deﬁcient
for expression of mouse β2 m and H-2Db. HHDII mice were bred and
maintained at the animal facility of the Milton S. Hershey Medical
Center under speciﬁc pathogen free conditions. All experiments using
mice were conducted in accordance with policies established by
the NIH under a protocol approved by the Institutional Animal Care
and Use Committee of the Pennsylvania State University College of
Medicine.
Peptides and viruses
Peptides were synthesized in the Macromolecular Synthesis Core
Facility at The Pennsylvania State University College of Medicine by 9-
ﬂuroenylmethoxycarbonyl chemistry using an automated peptide
synthesizer (9050 MilliGen PepSynthesizer). Peptides were solubilized
in DMSO and diluted to the appropriate concentrationwith RPMI 1640.
Amino acid sequences of the peptides used in the present study are
shown in Fig. 1. Wild type SV40 strain VA 45–54 was propogated as
previously described (Tevethia et al., 1974). The vaccinia virus recombi-
nants rVV-A2.1, which encodes the human HLA-A⁎0201 heavy chain
(O'Neil et al.,1993), and rVV-Kd,which encodes themurineH-2Kd heavy
chain (Bacik et al., 1994) were generously provided by Drs. Jonathan
Yewdell and Jack Bennink (National Institute of Allergy and Infectious
Diseases, Bethesda, MD). Vaccinia virus recombinants expressing the
VP1 determinants JCp100 (rVV-ES-JCp100), BKp108 (rVV-ES-BKp108)
and SVp110 (rVV-ES-SVp110) or SV40 T antigen determinant 281–289
(KCDDVLLLL; rVV-ES-SVT281) preceded by the endoplasmic reticulum
insertion sequence from the adenovirus E19 protein were engineered
and propagated as described previously (Fu et al., 1998).
Cell lines and media
TC7 monkey kidney cells were maintained in Dulbecco's Modiﬁed
Eagle's medium supplemented with 100 U/ml penicillin, 100 μg/ml
streptomycin, 100 μg/ml kanamycin, 2 mM L-glutamine, 10 mM HEPES
buffer, 0.075% (w/v) NaHCO3, and 5–10% FBS. TAP-deﬁcient T2 cells
(Salter et al., 1985) were maintained in RPMI 1640 supplemented with
10% FBS,100U/ml penicillin,100 μg/ml streptomycin, 2mML-glutamine,
50 μM 2-mercaptoethanol, and 25 μg/ml sodium pyruvate.
Peptide-induced stabilization of HLA-A⁎0201 molecules
Peptide-induced stabilization of HLA-A⁎0201 molecules on the
surface of T2 cells was performed as previously described (Schell et al.,
2001) and detected by ﬂow cytometry after staining with mAb BB7.2
(ATCC HB 82) and secondary detection with goat anti-mouse IgG. The
H-2Kb-binding gB498-505 (SSIEFARL) peptide from Herpes Simplex
Virus glycoprotein B (Bonneau et al., 1993) was used as a negative
control for these experiments.
Immunizations and in vitro culture of lymphocytes
HHDII mice were immunized subcutaneously at the base of the tail
with 100 μg of speciﬁc VP1-derived peptide or SV40 T antigen peptide
281–289 (KCDDVLLLL) (Schell et al., 2001) and 160 μg of the HBV core
helper peptide 128–140 emulsiﬁed in 100 μl of incomplete Freund's
adjuvant as described previously (Schell et al., 2001). A booster dose of
the same peptide was administered two weeks later. Immunized mice
were sacriﬁced and spleens harvested one week following the booster
immunization. For immunization with rVVs, mice received 107 PFU of
the indicated viruses by intravenous injection into the tail vein and
spleen cells were harvested after 10 days for ex vivo analysis. For in vitro
culture of lymphocytes, single cell suspensions of RBC-depleted sple-
nocytes were co-cultured with peptide pulsed syngeneic bonemarrow-
derived dendritic cells (DCs). DC's were isolated from the bone
189H.R.S. Tagaram et al. / Virology 376 (2008) 183–190marrow and maintained in culture with GM-CSF-containing super-
natant from X-63GM.1 cells (Norbury et al., 1997) essentially as
described (Lutz et al., 1999). In brief, bone marrow was ﬂushed from
the femurs of HHDII mice with RPMI-1640. The resulting cells were
cultured in 100mmpetri dishes at 4×106 cells/dish in 10ml of complete
RPMI-1640 medium supplemented with 10% heat inactivated FBS and
10%X-63GM.1 supernatant. On day 3,10ml of freshmediawas added to
the cultures. On days 6 and 9, 10 ml of supernatant was removed from
each dish and any ﬂoating cells recovered by centrifugation, resus-
pended in 10 ml of fresh media and added back to the original dish. On
day 11, the cells were harvested, frozen and stored at −80 °C until use.
Purity of CD11c+ cells at day 11 was between 70–80%. For T cell
stimulation, DCswere resuspendedat 1×106/ml in complete RPMI-1640
plus 100 nM speciﬁc peptide and incubated at 37 °Cwith rocking for 1 h
followed by two washes to remove excess peptide. DCs were irradiated
3000 rads using a 60Co-source GammaCell irradiator (MDS Nordion). A
total of 5×105 peptide pulsed DCs was co-cultured with 1×107
splenocytes from immunized HHDII mice in 4 ml of complete RPMI-
1640 medium containing 10% FBS. T lymphocyte cultures were
maintained in vitro by weekly passage with peptide pulsed DCs but
with the addition of 5 U/ml recombinant human IL-2 (Amgen).
Intracellular cytokine assays
After 6 days of culture, splenocytes were tested for IFN-γ production
by intracellular cytokine staining (ICS). Onemillion responder cellswere
stimulated with 1 μM of the indicated VP1 peptides, SVT281 peptide or
the unrelated HLA-A⁎-0201-binding HIV gag p17 (SLYNTVATL) peptide
plus 1 μg/ml of brefeldin A for 5 h at 37 °C. In some assays 10-fold
dilutions of the indicated peptideswere used. Cellswere stained for CD8
and IFN-γ using the Cytoﬁx/Cytoperm kit (Pharmagen) as described by
the manufacturer. Cells were ﬁxed with 2% paraformaldehyde and
analyzed by ﬂowcytometry using a FACSCalibur ﬂowcytometer (Becton
Dickinson) and the data analyzed using FlowJo software (Treestar).
Cytotoxicity assays
Cytotoxicity of the responding splenocyte cultures was assessed
using a standard 51Cr-release assay as described previously (Schell
et al., 1999). Brieﬂy, monolayers of TC7 cells were infected with SV40
strain VA 45–54 (MOI of 10) for 48 h and then superinfected with rVV-
A2.1 or rVV-Kd (MOI of 1) for 4 h in the presence of 200 μCi of sodium
51chromate. Cells from lymphocyte cultures were mixed with the
infected TC7 cells at the indicated ratios and incubated for 4 h at 37 °C,
5% CO2 after which 100 μl of supernatant was collected and counted on
a Cobra gamma-counter (Packard Instruments). Percent speciﬁc lysis
was determined as described previously (Schell et al., 1999). All data
represent the means of triplicate samples. Spontaneous release values
for TC7 cells co-infected with SV40 and vaccinia virus recombinants
were consistently around 30%.
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